Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: sunitinib alone|DRUG: sunitinib plus paclitaxel|DRUG: doxorubicin and cyclophosphamide
Sponsor: Indiana University
Collaborators: Pfizer